Ludwig Announces Acquisition of Intellectual Property and Patent
Ludwig Enterprises (OTC PINK:LUDG) has acquired intellectual property and patents for mRNA Neuro Panel and Serotonin Assay, including accumulated test data. This acquisition enables the use of mRNA genetic biomarkers to study brain inflammation in diseases like autism, PTSD, Parkinson's, and Alzheimer's. The company has also acquired breakthrough technology for measuring serotonin levels in salivary exosomes. The acquisition includes a U.S. Patent Application, international publication, serotonin assays developed at the University of Central Florida, and work product from Autism Spectrum Disorder and Fragile X Syndrome studies. Ludwig plans to start its screening business with breast cancer and expand to other diseases.
Ludwig Enterprises (OTC PINK:LUDG) ha acquisito proprietà intellettuale e brevetti per il mRNA Neuro Panel e l'Assay della Serotonina, compresi i dati di test accumulati. Questa acquisizione consente l'uso di biomarcatori genetici mRNA per studiare l'infiammazione cerebrale in malattie come l'autismo, il PTSD, il morbo di Parkinson e l'Alzheimer. L'azienda ha anche acquisito una tecnologia innovativa per misurare i livelli di serotonina negli eseomi salivari. L'acquisizione include una domanda di brevetto negli Stati Uniti, una pubblicazione internazionale, assayed di serotonina sviluppati presso l'Università della Florida Centrale e prodotti di lavoro derivanti da studi su Disturbo dello Spettro Autistico e Sindrome dell'X Fragile. Ludwig prevede di avviare la sua attività di screening con il cancro al seno ed espandersi ad altre malattie.
Ludwig Enterprises (OTC PINK:LUDG) ha adquirido propiedad intelectual y patentes para el mRNA Neuro Panel y el Assay de Serotonina, incluyendo datos acumulados de pruebas. Esta adquisición permite el uso de bimarcadores genéticos de mRNA para estudiar la inflamación cerebral en enfermedades como el autismo, el PTSD, el Parkinson y el Alzheimer. La empresa también ha adquirido tecnología innovadora para medir los niveles de serotonina en exosomas salivales. La adquisición incluye una Solicitud de Patente en EE.UU., una publicación internacional, ensayos de serotonina desarrollados en la Universidad de Florida Central, y productos de trabajo de estudios sobre el Trastorno del Espectro Autista y el Síndrome del X Frágil. Ludwig planea iniciar su negocio de detección con el cáncer de mama y expandirse a otras enfermedades.
루트빅 엔터프라이즈(OTC PINK:LUDG)는 지적 재산권 및 특허를 인수하여 mRNA 신경 패널 및 세로토닌 분석을 포함한 축적된 시험 데이터를 가져왔습니다. 이 인수는 mRNA 유전자 바이오마커를 사용하여 자폐증, PTSD, 파킨슨병 및 알츠하이머와 같은 질병의 뇌 염증을 연구할 수 있게 해줍니다. 또한, 회사는 타액 엑소좀에서 세로토닌 수치를 측정하는 혁신적인 기술을 인수했습니다. 이 인수는 미국 특허 출원, 국제 출판, 플로리다 중앙 대학교에서 개발된 세로토닌 분석 및 자폐 스펙트럼 장애와 취약한 X 증후군 연구에서의 작업 제품을 포함합니다. 루트빅은 유방암으로 스크리닝 사업을 시작하고 다른 질병으로 확장할 계획입니다.
Ludwig Enterprises (OTC PINK:LUDG) a acquis des droits de propriété intellectuelle et des brevets pour le mRNA Neuro Panel et l'Assay de Sérotonine, y compris les données de test accumulées. Cette acquisition permet l'utilisation de biomarqueurs génétiques mRNA pour étudier l'inflammation du cerveau dans des maladies telles que l'autisme, le PTSD, la maladie de Parkinson et la maladie d'Alzheimer. L'entreprise a également acquis une technologie révolutionnaire pour mesurer les niveaux de sérotonine dans les exosomes salivaires. L'acquisition comprend une demande de brevet aux États-Unis, une publication internationale, des assays de sérotonine développés à l'Université de Floride centrale et des produits de travail issus d'études sur le Trouble du Spectre Autistique et le Syndrome du X Fragile. Ludwig prévoit de commencer son activité de dépistage avec le cancer du sein et de s'étendre à d'autres maladies.
Ludwig Enterprises (OTC PINK:LUDG) hat geistiges Eigentum und Patente für das mRNA Neuro Panel und den Serotonin-Test erworben, einschließlich gesammelter Testdaten. Diese Übernahme ermöglicht den Einsatz von mRNA genetischen Biomarkern, um die Gehirnentzündung bei Krankheiten wie Autismus, PTSD, Parkinson und Alzheimer zu untersuchen. Das Unternehmen hat auch bahnbrechende Technologie zur Messung der Serotoninspiegel in speicheligen Exosomen erworben. Die Übernahme umfasst einen Patentantrag in den USA, internationale Veröffentlichung, Serotonin-Assays, die an der University of Central Florida entwickelt wurden, und Arbeitsprodukte aus Studien zu Autismus-Spektrum-Störungen und Fragiler-X-Syndrom. Ludwig plant, sein Screening-Geschäft mit Brustkrebs zu beginnen und auf andere Krankheiten auszuweiten.
- Acquisition of intellectual property and patents for mRNA Neuro Panel and Serotonin Assay
- Enables study of brain inflammation in various neurological diseases using mRNA genetic biomarkers
- Breakthrough technology for measuring serotonin levels in salivary exosomes
- Potential for expanding into multiple disease indications for screening
- Plans to start screening business with breast cancer
- None.
SPARKS, NV / ACCESSWIRE / September 17, 2024 / Ludwig Enterprises, Inc., (OTC PINK:LUDG), a USA-based biotechnology company, is pleased to announce it has acquired all the intellectual property and patent of the mRNA Neuro Panel and Serotonin Assay, along with all the data accumulated testing these Assays.
Significance of acquisition:
Allows use of mRNA genetic biomarkers to study inflammatory changes in the brain in such diseases as autism, post-traumatic stress disorder (PTSD), Parkinson's disease, Alzheimer's disease, multiple sclerosis, ALS, etc.
Acquisition of breakthrough technology in measuring serotonin levels in salivary exosomes. Serotonin, or 5-hydroxytryptamine (5-HT), is a neurotransmitter with an integral physiological role in the human body; it regulates various activities, including behavior, mood, memory, and gastrointestinal homeostasis.
Serotonin has a wide variety of functions in the human body. People sometimes call it the "happy" chemical because it contributes to well-being and happiness. Serotonin appears to affect mood, emotions, appetite, and digestion. As the precursor for melatonin, it helps regulate sleep-wake cycles and the body clock.
Analysis of autism questionnaire statements from ASD families or caregivers revealed an association between mRNA inflammatory markers and ASD survey responses. These score results open the door to the use of our mRNA neuroinflammatory markers in the diagnosis, evaluation, and treatment responses of ASD individuals. Survey questions include eye contact, social interaction, anxiety, etc.
Ludwig acquired the following:
U.S. Patent Application 18/705375, International Publication Number WO 2023/077245, captioned as "Diagnosing, Monitoring and Treating Neurological Disease with Psychoactive Tryptamine Derivatives and mRNA Measurements.
Serotonin assay(s) being developed by Dr. Kiminobu Sugaya at the University of Central Florida, including preclinical and clinical data.
Work product and output of the Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FSX) Patient Observational Study.
"These patents represent the culmination of over 10 years of work in the field of mRNA research." said Marvin S. Hausman, MD, Chief Science Officer of Ludwig Enterprises. "We think mRNA neurologic testing represents next-gen diagnostics that will bring affordable screening technology to the masses. It's well known that the quicker we uncover a disease, the greater the chance we will successfully treat it. We intend to start our screening business with breast cancer but hope to quickly expand to other disease indications like autism, PTSD, Alzheimer's, and Parkinson's."
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. AI technology is used to extrapolate inflammatory signals that are correlated to different types of cancer and chronic diseases. The company developed an early screening cancer diagnostic kit Revealia™ utilizing a mail-order cheek swab that is sold directly to consumers. The proprietary test is patent-pending and contains multi-cancer early detection screening technology in a painless convenient solution that is highly accurate compared to alternative early screening test kits. The core research driving the diagnostic business opportunities comes from the ongoing identification and monitoring of patients that present varying degrees of chronic inflammation which is the causative agent of illnesses such as cancer and heart disease, which are responsible for more than
For more information please visit: http://www.ludwigent.com. https://www.revealia.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
Antonia Reyes, CEO
www.ludwigent.com
Investor Relations
Resources Unlimited NW LLC
Mike Sheikh, Investor Relations
mike@resourcesunlimtedllc.com
Contact Information
Mike Sheikh
Investor Relations
mike@resourcesunlimtedllc.com
SOURCE: Ludwig Enterprises, Inc.
View the original press release on accesswire.com
FAQ
What intellectual property did Ludwig Enterprises (LUDG) acquire in September 2024?
How will the acquired technology benefit Ludwig Enterprises (LUDG)?
What are Ludwig Enterprises' (LUDG) plans for the newly acquired technology?
What specific patents and applications did Ludwig Enterprises (LUDG) acquire?
